{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:28:41Z","timestamp":1791829721285,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T00:00:00Z","timestamp":1531094400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (National Science Foundation of China)","doi-asserted-by":"publisher","award":["61301294"],"award-info":[{"award-number":["61301294"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1038\/s41391-018-0059-4","type":"journal-article","created":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T09:39:17Z","timestamp":1531129157000},"page":"451-460","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"21","author":[{"given":"Zhenlang","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leiliang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franky Leung","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiming","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songtao","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,9]]},"reference":[{"key":"59_CR1","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1002\/ijc.25516","volume":"127","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893\u2013917.","journal-title":"Int J Cancer"},{"key":"59_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1191\/0748233705th238oa","volume":"21","author":"A Buja","year":"2005","unstructured":"Buja A, Lange JH, Perissinotto E, Rausa G, Grigoletto F, Canova C, Mastrangelo G. Cancer incidence among male military and civil pilots and flight attendants: an analysis on published data. Toxicol Ind Health. 2005;21:273\u201382.","journal-title":"Toxicol Ind Health"},{"key":"59_CR3","unstructured":"FDA Drug Safety Communication. FDA requests label changes and single use packaging for some over-the-counter topical antiseptic products to decrease risk of infection. Clin Infect Dis. 2014;58:i\u2013ii."},{"key":"59_CR4","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1001\/jamaoncol.2016.1143","volume":"2","author":"AD Falchook","year":"2016","unstructured":"Falchook AD, Basak R, Mohiuddin JJ, et al. Use of androgen deprivation therapy with radiotherapy for intermediate-and high-risk prostate cancer across the United States. JAMA Oncol. 2016;2:1236\u20138.","journal-title":"JAMA Oncol"},{"key":"59_CR5","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1001\/jamaoncol.2016.3138","volume":"2","author":"L Klotz","year":"2016","unstructured":"Klotz L, Higano CS. Intermittent androgen deprivation therapy-an important treatment option for prostate Cancer. JAMA Oncol. 2016;2:1531\u20132.","journal-title":"JAMA Oncol"},{"key":"59_CR6","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1200\/JCO.2014.57.2743","volume":"33","author":"JE Bekelman","year":"2015","unstructured":"Bekelman JE, Mitra N, Handorf EA, et al. Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer. J Clin Oncol. 2015;33:716\u201322.","journal-title":"J Clin Oncol"},{"key":"59_CR7","first-page":"716","volume":"10","author":"JY Bruce","year":"2012","unstructured":"Bruce JY, Lang JM, McNeel DG, et al. Current controversies in the management of biochemical failure in prostate cancer. Clin Adv Hematol Oncol. 2012;10:716\u201322.","journal-title":"Clin Adv Hematol Oncol"},{"key":"59_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nrurol.2014.119","volume":"11","author":"O Sartor","year":"2014","unstructured":"Sartor O, Silberstein J. Prostate cancer: primary ADT monotherapy not suitable for localized disease. Nat Rev Urol. 2014;11:309\u201310.","journal-title":"Nat Rev Urol"},{"key":"59_CR9","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.urolonc.2009.09.004","volume":"29","author":"SM Gilbert","year":"2011","unstructured":"Gilbert SM, Kuo YF, Shahinian VB. Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. Urol Oncol. 2011;29:647\u201353.","journal-title":"Urol Oncol"},{"key":"59_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.eururo.2014.10.018","volume":"68","author":"JD Sammon","year":"2015","unstructured":"Sammon JD, Abdollah F, Reznor G, et al. Patterns of declining use and the adverse effect of primary androgen deprivation on all-cause mortality in elderly men with prostate cancer. Eur Urol. 2015;68:32\u20139.","journal-title":"Eur Urol"},{"key":"59_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.eururo.2007.09.002","volume":"53","author":"A Heidenreich","year":"2008","unstructured":"Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68\u201380.","journal-title":"Eur Urol"},{"key":"59_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jnci\/djp404","volume":"102","author":"NL Keating","year":"2010","unstructured":"Keating NL, O\u2019 Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102:39\u201346.","journal-title":"J Natl Cancer Inst"},{"key":"59_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.thromres.2007.03.008","volume":"121","author":"S Li","year":"2007","unstructured":"Li S, Li X, Li J, et al. Experimental arterial thrombosis regulated by androgen and its receptor via modulation of platelet activation. Thromb Res. 2007;121:127\u201334.","journal-title":"Thromb Res"},{"key":"59_CR14","doi-asserted-by":"publisher","first-page":"e107516","DOI":"10.1371\/journal.pone.0107516","volume":"9","author":"J Zhao","year":"2014","unstructured":"Zhao J, Zhu S, Sun L, et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS One. 2014;9:e107516.","journal-title":"PLoS One"},{"key":"59_CR15","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.eururo.2011.08.041","volume":"60","author":"L Azoulay","year":"2011","unstructured":"Azoulay L, Yin H, Benayoun S, et al. Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol. 2011;60:1244\u201350.","journal-title":"Eur Urol"},{"key":"59_CR16","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.eururo.2012.01.045","volume":"61","author":"JC Hu","year":"2012","unstructured":"Hu JC, Williams SB, O\u2019Malley AJ, et al. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol. 2012;61:1119\u201328.","journal-title":"Eur Urol"},{"key":"59_CR17","doi-asserted-by":"publisher","first-page":"e976","DOI":"10.1016\/S1569-9056(14)60960-X","volume":"13","author":"M Nguyen-Nielsen","year":"2014","unstructured":"Nguyen-Nielsen M, Borre M, Horv\u00e1th-Puh\u00f3 E, et al. Risk of venous thromboembolism among prostate cancer patients treated with androgen deprivation therapy in Denmark: a population-based cohort study, 1997-2011. Eur Urol Suppl. 2014;13:e976.","journal-title":"Eur Urol Suppl"},{"key":"59_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.eururo.2015.06.022","volume":"70","author":"AJ Klil-Drori","year":"2016","unstructured":"Klil-Drori AJ, Yin H, Tagalakis V, et al. Androgen deprivation therapy for prostate cancer and the risk of venous thromboembolism. Eur Urol. 2016;70:56\u201361.","journal-title":"Eur Urol"},{"key":"59_CR19","unstructured":"Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration. 2011. \n                    www.cochrane-handbook.org\n                    \n                  ."},{"key":"59_CR20","doi-asserted-by":"publisher","first-page":"2008e12","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283:2008e12.","journal-title":"JAMA"},{"key":"59_CR21","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of non-randomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603\u20135.","journal-title":"Eur J Epidemiol"},{"key":"59_CR22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629.","journal-title":"BMJ"},{"key":"59_CR23","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045(10)70038-3","volume":"11","author":"M Hemelrijck Van","year":"2010","unstructured":"Van Hemelrijck M, Adolfsson J, Garmo H, et al. Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol. 2010;11:450\u20138.","journal-title":"Lancet Oncol"},{"key":"59_CR24","first-page":"36","volume":"24","author":"SC Yii","year":"2017","unstructured":"Yii SC, Chung SD, Huang CY. The association between androgen deprivation therapy and pulmonary embolism: a population-based study. J Urol. 2017;24:36\u20137.","journal-title":"J Urol"},{"key":"59_CR25","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/sim.1752","volume":"23","author":"JPT Higgins","year":"2004","unstructured":"Higgins JPT, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med. 2004;23:1663\u201382.","journal-title":"Stat Med"},{"key":"59_CR26","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1002\/sim.1482","volume":"22","author":"G Knapp","year":"2003","unstructured":"Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. Stat Med. 2003;22:2693\u2013710.","journal-title":"Stat Med"},{"key":"59_CR27","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1002\/cncr.26623","volume":"118","author":"B Ehdaie","year":"2012","unstructured":"Ehdaie B, Atoria CL, Gupta A, et al. Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer. 2012;118:3397\u2013406.","journal-title":"Cancer"},{"key":"59_CR28","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/bju.13360","volume":"118","author":"S O\u2019 Farrell","year":"2016","unstructured":"O\u2019 Farrell S, Sandstr\u00f6m K, Garmo H, et al. Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy. BJU Int. 2016;118:391\u20138.","journal-title":"BJU Int"},{"key":"59_CR29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/00005792-199909000-00001","volume":"78","author":"N Levitan","year":"1999","unstructured":"Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78:285\u201391.","journal-title":"Medicine (Baltimore)"},{"key":"59_CR30","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/jnci\/85.12.979","volume":"85","author":"BW Brown","year":"1993","unstructured":"Brown BW, Brauner C, Minnotte MC. Noncancer deaths in white adult cancer patients. J Natl Cancer Inst. 1993;85:979\u201387.","journal-title":"J Natl Cancer Inst"},{"key":"59_CR31","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1002\/cncr.20955","volume":"103","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL, et al. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103:1615\u201324.","journal-title":"Cancer"},{"key":"59_CR32","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1056\/NEJMsa0910784","volume":"363","author":"VB Shahinian","year":"2010","unstructured":"Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med. 2010;363:1822\u201332.","journal-title":"N Engl J Med"},{"key":"59_CR33","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1002\/cncr.23421","volume":"112","author":"CJ Weight","year":"2008","unstructured":"Weight CJ, Klein EA, Jones JS. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population. Cancer. 2008;112:2195\u2013201.","journal-title":"Cancer"},{"key":"59_CR34","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1210\/jc.2005-2507","volume":"91","author":"MR Smith","year":"2006","unstructured":"Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91:1305\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"59_CR35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1042\/cs1040195","volume":"104","author":"F Dockery","year":"2003","unstructured":"Dockery F, Bulpitt CJ, Agarwal S, et al. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond). 2003;104:195\u2013201.","journal-title":"Clin Sci (Lond)"},{"key":"59_CR36","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","volume":"360","author":"M Bolla","year":"2009","unstructured":"Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360:2516\u201327.","journal-title":"N Engl J Med"},{"key":"59_CR37","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/cncr.22628","volume":"109","author":"AV D\u2019 Amico","year":"2007","unstructured":"D\u2019 Amico AV, Denham JW, Bolla M, et al. Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate. Cancer. 2007;109:2004\u201310.","journal-title":"Cancer"},{"key":"59_CR38","doi-asserted-by":"publisher","first-page":"e259","DOI":"10.1016\/S1470-2045(12)70084-0","volume":"13","author":"ZS Zumsteg","year":"2012","unstructured":"Zumsteg ZS, Zelefsky MJ. Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care? Lancet Oncol. 2012;13:e259\u2013e269.","journal-title":"Lancet Oncol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41391-018-0059-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-018-0059-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-018-0059-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:33:18Z","timestamp":1684603998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-018-0059-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,9]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["59"],"URL":"https:\/\/doi.org\/10.1038\/s41391-018-0059-4","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,9]]},"assertion":[{"value":"4 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}